Back to top
more

Rocket Pharmaceuticals (RCKT)

(Delayed Data from NSDQ)

$21.98 USD

21.98
878,742

-0.12 (-0.54%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

by Zacks Equity Research

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?

by Zacks Equity Research

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates

by Zacks Equity Research

Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.

Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 167.1% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week

by Zacks Equity Research

Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.

Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates

by Zacks Equity Research

Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.

Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag

by Zacks Equity Research

The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. The stock gains 2.3% following the news.

Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Rocket Pharmaceuticals (RCKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 170.9% upside potential for Rocket Pharmaceuticals (RCKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to an 183.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 211.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

New Strong Sell Stocks for March 10th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

5 Medical Outperformers That Might Lose Steam in 2021

by Zacks Equity Research

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

    Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data

    by Zacks Equity Research

    Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.

    Rocket Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    by Zacks Equity Research

    Rocket Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

    Why Rocket (RCKT) Stock Might be a Great Pick

    by Zacks Equity Research

    Rocket (RCKT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

    Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy

    by Zacks Equity Research

    Does Rocket Pharmaceuticals (RCKT) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to Buy

    by Zacks Equity Research

    Does Rocket Pharmaceuticals (RCKT) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in Rocket Pharmaceuticals, Inc. (RCKT).

    Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher

    by Zacks Equity Research

    Rocket Pharmaceuticals (RCKT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.